RemeGen (OTCMKTS:REGMF) Shares Down 8.9% – What’s Next?

by · The Cerbat Gem

RemeGen Co., Ltd. (OTCMKTS:REGMF – Get Free Report)’s share price traded down 8.9% during trading on Friday . The company traded as low as $9.96 and last traded at $9.96. 300 shares changed hands during trading, a decline of 67% from the average session volume of 917 shares. The stock had previously closed at $10.93.

RemeGen Price Performance

The firm has a 50 day simple moving average of $11.06 and a 200-day simple moving average of $10.76.

About RemeGen

(Get Free Report)

RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.

RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.

Further Reading